Fujian Cosunter Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Fujian Cosunter Pharmaceutical's earnings have been declining at an average annual rate of -77.5%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 0.9% per year.
Key information
-77.5%
Earnings growth rate
-77.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -0.9% |
| Return on equity | -57.5% |
| Net Margin | -66.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Fujian Cosunter Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 455 | -300 | 305 | 93 |
| 31 Dec 23 | 423 | -349 | 306 | 133 |
| 30 Sep 23 | 368 | -252 | 284 | 158 |
| 30 Jun 23 | 371 | -258 | 280 | 199 |
| 31 Mar 23 | 377 | -182 | 274 | 207 |
| 31 Dec 22 | 386 | -127 | 263 | 185 |
| 30 Sep 22 | 397 | -86 | 255 | 145 |
| 30 Jun 22 | 390 | -44 | 247 | 106 |
| 31 Mar 22 | 372 | -46 | 241 | 79 |
| 01 Jan 22 | 370 | -35 | 235 | 69 |
| 30 Sep 21 | 369 | -21 | 224 | 62 |
| 30 Jun 21 | 369 | -14 | 215 | 57 |
| 31 Mar 21 | 380 | 15 | 199 | 52 |
| 31 Dec 20 | 368 | 15 | 191 | 47 |
| 30 Sep 20 | 363 | 12 | 195 | 44 |
| 30 Jun 20 | 373 | 11 | 212 | 43 |
| 31 Mar 20 | 389 | 5 | 236 | 52 |
| 31 Dec 19 | 415 | 11 | 259 | 53 |
| 30 Sep 19 | 439 | 24 | 281 | 57 |
| 30 Jun 19 | 455 | 23 | 295 | 61 |
| 31 Mar 19 | 424 | 12 | 284 | 63 |
| 31 Dec 18 | 402 | 16 | 258 | 70 |
| 30 Sep 18 | 359 | 10 | 231 | 66 |
| 30 Jun 18 | 308 | 11 | 167 | 97 |
| 31 Mar 18 | 301 | 25 | 166 | 78 |
| 31 Dec 17 | 296 | 34 | 172 | 59 |
| 30 Sep 17 | 308 | 37 | 191 | 45 |
| 30 Jun 17 | 314 | 53 | 220 | 0 |
| 31 Mar 17 | 314 | 59 | 212 | 0 |
| 31 Dec 16 | 313 | 66 | 203 | 0 |
| 30 Sep 16 | 309 | 80 | 182 | 0 |
| 30 Jun 16 | 314 | 92 | 175 | 0 |
| 31 Mar 16 | 319 | 104 | 166 | 0 |
| 31 Dec 15 | 309 | 103 | 156 | 0 |
| 30 Sep 15 | 297 | 101 | 144 | 0 |
| 30 Jun 15 | 283 | 95 | 134 | 0 |
| 31 Mar 15 | 268 | 91 | 123 | 0 |
| 31 Dec 14 | 254 | 84 | 119 | 0 |
| 31 Dec 13 | 178 | 57 | 84 | 0 |
Quality Earnings: 300436 is currently unprofitable.
Growing Profit Margin: 300436 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300436 is unprofitable, and losses have increased over the past 5 years at a rate of 77.5% per year.
Accelerating Growth: Unable to compare 300436's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300436 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 300436 has a negative Return on Equity (-57.53%), as it is currently unprofitable.